Chronic lymphocytic leukaemia
Not recruitingStudy on Acalabrutinib and Venetoclax for Newly Diagnosed Chronic Lymphocytic Leukemia Patients at High Risk of Infection and Early Treatment Needs
Study on Acalabrutinib and Venetoclax for Newly Diagnosed Chronic Lymphocytic Leukemia Patients at High Risk of Infection and Early Treatment Needs
- Disease:Chronic lymphocytic leukaemia
- Substances:AcalabrutinibVenetoclax
Sweden- Participants:18–64 years · 65+ years
- Substances:Acalabrutinib
- Sponsor:Region Hovedstaden















